# ANANDRATHI

28 November 2017

## **PSP Projects**

Strong growth momentum; WC-cycle prolongation an aberration

Q2, post-listing, is as inspiring as Q1, with the strong growth pace persisting for PSP. The working-capital-cycle elongation seems to be a GST-led aberration. As this is expected to correct shortly and as recently-bagged projects begin to contribute, we see the healthy growth momentum continuing. Also, the opportunity landscape in its area of expertise (institutional buildings) is bright and recent fund raising would help make the most of it. We do not have a rating on the stock but a long-term admiration for the company's sound fundamentals.

Impressive year-to-date inflows. Backed by its largest ever single order (the Surat Diamond Bourse valued (excl. GST at  $\sim \mathbf{E}15.8$ bn), the company has secured orders of  $\sim \mathbf{E}23$ bn for the year till now. As inflows are far in excess of revenues recognized, revenue assurance has jumped manifold (at 5x TTM sales). With revenue assurance secure, project execution is likely to gain centre-stage but select bidding isn't ruled out (management expects another  $\sim \mathbf{E}4$ bn-5bn by the year end).

**Working-capital cycle prolonged but expected to contract.** Protraction in the cycle was largely due to an increase in receivables days (up from 49 at 31<sup>st</sup> Mar'17 to 86 at end-Q2). Management attributes this to GST-driven issues with billing and *adhoc* payments by some of the clients (probably, the held-back GST component).

**Competition keener for smaller projects.** Hyper-competition by smaller operators for orders of below ₹1.5bn is pricing out the company. For larger projects, competition is not as intense and rational bidding prevails.

Valuation. At the CMP, the stock trades at a PE of 29x TTM EPS of ~₹14.9. To justify such a high valuation, PSP would have to deliver ~30% earnings CAGR in the next two years. Backed by a strong order backlog and continued focus on project execution, the targeted growth seems achievable. **Risks.** Any failure to maintain prudence.

Key financials (YE Mar)	FY13	FY14	FY15	FY16	FY17
Sales (₹ m)	2,572	2,104	2,805	4,580	4,008
Net profit (₹ m)	123	101	141	249	413
EPS (₹ )	4.3	3.5	4.9	8.7	14.3
Growth (%)	46.7	-17.8	39.6	77.4	65.7
PE (x)	103.2	125.5	89.9	50.7	30.6
EVEBITDA (x)	70.5	91.3	67.7	38.3	22.9
PBV (x)	59.4	45.4	33.7	23.9	14.7
RoE (%)	58.5	32.8	34.4	44.1	47.6
RoCE (%)	53.3	34.3	33.8	44.2	50.2
Net debt/equity (x)	-1.1	-1.5	-1.3	-1.1	-0.7
Source: Company Note: Standalone Finar	cials				

Prem Khurana Research Analyst +9122 6626 6470 premkhurana@rathi.com


Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

## Rating: NR

Share Price: ₹439

Key data	PSPPL IN / PSPP.BO
52-week high / low	₹469 / 189
Sensex / Nifty	33724 / 10400
3-m average volume	\$0.7m
Market cap	₹16bn / \$244m
Shares outstanding	36m

Shareholding pattern (%)	Sep'17	Jun'17	May'17
Promoters	72.0	72.0	72.0
- of which, Pledged	-	-	-
Free Float	28.0	28.0	28.0
- Foreign Institutions	1.2	1.1	2.5
- Domestic Institutions	10.5	13.6	13.8
- Public	16.3	13.4	11.7




### Construction

**India | Equities** 

## **Quick Glance – Financials and Valuations**

Fig 1 – Income statement (₹ m) - Standalone								
Year-end: Mar	FY13	FY14	FY15	FY16	FY17			
Order Backlog	NA	4,472	4,877	3,381	7,292			
Average order size	NA	244	198	192	351			
Net revenues (₹ m)	2,572	2,104	2,805	4,580	4,008			
Growth (%)	44.0	-18.2	33.3	63.3	-12.5			
Direct costs	2,232	1,858	2,489	4,032	3,188			
SG&A	121	79	92	155	161			
EBITDA	220	167	224	393	658			
EBITDA margins (%)	8.5	8.0	8.0	8.6	16.4			
Depreciation	37	37	52	71	76			
Other income	37	44	65	97	132			
Interest Exp	38	20	25	34	75			
PBT	182	154	213	386	639			
Effective tax rate (%)	32.7	34.6	33.9	35.4	35.4			
+ Associates/(Minorities)	-	-	-	-	-			
Net Income	123	101	141	249	413			
Adjusted income	123	101	141	249	413			
Growth (%)	46.7	-17.8	39.6	77.4	65.7			
FDEPS (₹/share)	4.3	3.5	4.9	8.7	14.3			

Fig 3 – Cash-flow statement (₹m) - Standalone								
Year-end: Mar	FY13	FY14	FY15	FY16	FY17			
PBT	182	154	213	386	639			
+ Non-cash items	37	37	52	71	76			
Oper. profit before WC chg	219	191	264	457	715			
- Incr./(decr.) in WC	-120	-102	-157	-150	420			
Others including taxes	59	53	72	137	226			
Operating cash-flow	280	239	349	470	69			
- Capex (tangible + Intangible)	42	37	201	258	71			
Free cash-flow	238	202	148	212	-2			
Acquisitions	-	-	-	-	-			
- Dividend*	9	19	19	58	-			
+ Equity raised	-	-	-	-	-			
+ Debt raised	-110	109	72	115	222			
- Fin Investments	32	54	37	53	36			
- Misc. Items (CFI + CFF)	0	(0)	0	-	-2			
Net cash-flow Source: Company	87	238	164	216	186			






Year-end: Mar	FY13	FY14	FY15	FY16	FY17
Share capital	8	8	8	32	288
Net worth*	266	348	469	661	1,076
Total debt	150	260	334	452	677
Minority interest	-	-	-	-	-
DTL/(assets)	-2	-3	-5	-9	-11
Capital employed	414	605	798	1,105	1,742
Net tangible assets	185	185	332	519	513
Net intangible assets	-	-	0	3	5
Goodwill	-	-	-	-	-
CWIP (tang. & intang.)	-	-	2	-	-
Investments (strategic)	35	8	8	50	76
Investments (financial)	-	81	118	130	140
Current assets (ex cash)	342	401	550	513	1,158
Cash	446	684	848	1,064	1,250
Current liabilities	594	755	1,060	1,174	1,399
Working capital	-252	-354	-511	-661	-241
Capital deployed	414	605	798	1,105	1,742
Contingent liabilities	177	183	457	727	1,178

### Fig 4 – Ratio analysis@ ₹439

Year-end: Mar	FY13	FY14	FY15	FY16	FY17
P/E (x)	103.2	125.5	89.9	50.7	30.6
EV/EBITDA (x)	70.5	91.3	67.7	38.3	22.9
EV/sales (x)	6.0	7.3	5.4	3.3	3.8
P/B (x)	59.4	45.4	33.7	23.9	14.7
RoE (%)	58.5	32.8	34.4	44.1	47.6
RoCE (%)	53.3	34.3	33.8	44.2	50.2
Sales/FA (x)	13.9	11.4	8.4	8.8	7.7
DPS (Rs per share)*	0.3	0.6	0.6	1.7	2.5
Dividend yield (%)*	0.1	0.1	0.1	0.4	0.6
Dividend payout (%) - Inc. DDT*	7.6	18.6	13.7	23.1	26.2
Net debt/equity (x)	-1.1	-1.5	-1.3	-1.1	-0.7
Receivables (days)	17	24	31	8	49
Inventory (days)	3	3	5	3	3
Payables (days)	50	69	82	55	63
CFO:PAT%	228.4	237.7	248.5	188.6	16.7
Source: Company ; * Dividend for FY17	proposed a	after IPO; c	onsidered	in ratio anal	lysis

### Fig 6 – Average order ticket size on an uptrend\*\*



## **Operations update / Concall highlights**


### **Financial performance**

- A robust pace of execution in the quarter, at ~₹7.5bn of the opening order backlog (attributable to the standalone entity) helped the company report a strong ~80% y/y growth in revenue. The growth is equally impressive for H1 FY18, at ~80%, implying there was no drop in pace of execution in Q2.
- The margin contracted ~113bps y/y to ~13.4% but is still better than the long-term median (~8.5% for the last six years). The margin contraction seems a function of the revenue mix as well as the project mix.
- A healthy jump in revenue, combined with contained finance costs (at ~1.4% of sales vs. ~2.3% a year ago) and higher other income (due to the higher cash balance) helped earnings double y/y (up ~102%).

Fig 7 – Financial I	nighlight	s						
(YE: Mar) (₹ m)	Q2 FY17	Q2 FY18	% y/y	Q1 FY18	% q/q	H1 FY17	H1 FY18	% y/y
Sales	776	1,396	79.7	1,558	(10.4)	1,637	2,954	80.4
EBITDA	112	186	65.7	199	(6.4)	231	385	67.0
EBITDA margin (%)	14.5	13.4	-113bps	12.8	58bps	14.1	13.1	-105bps
Interest	18	20	14.0	14	47.4	33	34	2.5
Depreciation	18	23	24.4	18	24.3	35	41	16.8
Other income	23	52	126.2	41	26.3	50	93	87.3
РВТ	99	195	96.5	208	(6.1)	212	403	90.1
Tax	37	69	87.3	72	(5.3)	75	141	89.5
Adjusted PAT	63	127	101.8	136	(6.6)	138	262	90.4
Source: Company								

## **Order backlog / inflows**

Backed by strong inflows of ~₹5.1bn in Q2, H1 inflows have been a healthy ~₹6.8bn. Consequently, the order backlog at 30th Sep'17 was ~₹11.5bn.



- Besides, subsequently, the company has secured its largest ever single order in the institutional buildings sub-segment. Valued at ~₹15.8bn (excl. GST), this institution order for the Surat Diamond Bourse is to be completed within 30 months. This takes the order backlog to ~₹27bn and implies a book-to-bill of 5x on reported TTM sales.
- With this healthy order backlog and work yet to stabilise at some of the new orders (especially on the Surat Diamond Bourse project), management intends to be very selective in bidding for projects. Nevertheless, it expects orders of another ~₹4bn-5bn in H2 FY18, based on the present bid pipeline and client comfort.
- In its Sep'17-end order backlog of ~₹11.5bn, government contracts account for ~13%. Management identify these as contracts with no pass through structure for any change in prices of any raw material.

## The Surat Diamond Bourse project

- Management expects to incur capex of ~4-5% of the project value for the Surat Diamond Bourse project, but does not see any need to dip into its own cash-flows to fund this. As per management, mobilisation advances of 5% from the project would ideally suffice for a large part of the required capex. Besides capex for the Surat Diamond Bourse, management is also looking at another ~₹0.3bn-0.4bn of capex over the next 1.5 years. Over H1 FY18, it incurred capex of ~₹109m.
- Management expects excavation to take three months, then foundation 4-6 months. A need for shuttering material would then arise.
- Management does not see the Surat Diamond Bourse project to be a cash drag since it is an activity-linked monthly-payment scheme. It sees mobilisation advances of ~₹0.8bn (excl. GST) to help the first payment milestone and kick-start the payment cycle. At any time, it does not see more than ~₹0.6bn of exposure to the project. Mobilisation advances in this project are adjustable against the receipts; to be adjusted over the entire project value (5% to be deducted from every payment due).
- Management expects this project to turn revenue contributing by Jan/ Feb'18.
- Management has been given to understand that L2 in this project was ~₹0.3bn-0.35bn higher than its bid of ₹15.75bn.
- It believes its credentials from completing a 1.8m sq.ft. housing project in Gujarat ahead of scheduled helped it qualify for the project.
- On the client's ability to pay, management has been given to understand that the client (Association of Diamond Merchants) has already sold ~85-90% of the saleable area and collected ~₹6bn as first instalment. The rest of the payments are to be received on a milestone basis.

## New opportunity / Competitive intensity

■ Management sees hyper-competition in sub-₹1.5bn orders. Thus, it is being priced out by smaller operators. For larger projects, competition is not as intense and rational bidding by large operators continues.

- Gujarat remains the company's mainstay. Management intends to conservatively explore opportunities outside that state. For such opportunities, its focus would continue on segments in which it already operates. The idea is to gradually strengthen capabilities outside Gujarat.
- It expects bidding for IIT in Hyderabad by mid- to end-Dec'17.
- Based on its present credentials and balance sheet, the company is well placed to bid for any single project of ₹5bn.

### **Capex / cash flows**

- During H1 FY18, the company incurred a capex of ~₹109m, funded from the issue proceeds. For the rest of the year, it expects to incur another ~₹0.3bn-0.4bn. This is besides the capex required for the Surat Diamond Bourse.
- Receivables have seen a meaningful increase in H1 FY18, from ~₹0.5bn on 31<sup>st</sup> Mar'17 (49 days) to ~₹1.3bn (86 days). Management attributes this to GST-driven issues, with billing and *adhoc* payments by clients in the mean time. Management expects the cycle to return to 40-45 days by Mar'18.
- Of the IPO proceeds of ~₹1.5bn, the company has utilized ~₹0.8bn (working capital ~₹0.55bn, capex ~₹109m and general purposes ~₹91m).

## **Valuation**

At the CMP, the stock trades at PE of 29x TTM EPS of ~₹14.9. To justify such a high valuation, PSP would have to deliver ~30% earnings CAGR in the next two years. Backed by a strong order backlog and continued focus on project execution, the targeted growth seems achievable.

Risks. Any failure to maintain prudence.

#### Appendix

#### Analyst Certification

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

#### Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps (>US\$1bn) and Mid/Small Caps (<US\$1bn) as described in the Ratings Table below:

Ratings Guide (12 months)				
	Buy	Hold	Sell	
Large Caps (>US\$1bn)	>15%	5-15%	<5%	
Mid/Small Caps ( <us\$1bn)< td=""><td>&gt;25%</td><td>5-25%</td><td>&lt;5%</td><td></td></us\$1bn)<>	>25%	5-25%	<5%	

#### Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity) is a subsidiary of Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd, National Stock Exchange of India Ltd. (NSEIL), Multi Stock Exchange of India Ltd (MCX-SX), United Stock Exchange and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. ARSSBL is engaged in the business of Stock Broking, Depository Participant and Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

#### Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report? ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No No
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No

#### Other Disclosures pertaining to distribution of research in the United States of America

This report was prepared, approved, published and distributed by the Anand Rathi Share and Stock Brokers Limited (ARSSBL) located outside of the United States (a "non-US Group Company"). This report is distributed in the U.S. by Enclave Capital LLC, a U.S. registered broker dealer, on behalf of ARSSBL only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act")) pursuant to the exemption in Rule 15a-6 and any transaction effected by a U.S. customer in the securities described in this report must be effected through Enclave Capital. ARSSBL accepts responsibility for its contents. Any US customer wishing to effect transactions in any securities referred to herein or options thereon should do so only by contacting a representative of Enclave Capital LLC at 646-454-8600

Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization.

This material was produced by ARSSBL, solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. It is distributed in the United States of America by Enclave Capital LLC (19 West 44th Street, Suite 1700, New York, NY 10036) and elsewhere in the world by ARSSBL or an authorized affiliate of ARSSBL (such entities and any other entity, directly or indirectly, controlled by ARSSBL, the "Affiliates"). This document does not constitute an offer of, or an invitation by or on behalf of ARSSBL or its Affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which ARSSBL or its Affiliates consider to be reliable. None of ARSSBL or its Affiliates accepts any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions.

1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.

2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.

3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.

4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.

5. As of the publication of this report, ARSSBL does not make a market in the subject securities.

6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

Enclave Capital LLC is distributing this document in the United States of America. ARSSBL accepts responsibility for its contents. Any US customer wishing to effect transactions in any securities referred to herein or options thereon should do so only by contacting a representative of Enclave Capital LLC.

© 2016. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

Additional information on recommended securities/instruments is available on request.

ARSSBL registered address: 4th Floor, Silver Metropolis, Jaicoach Compound, Opposite Bimbisar Nagar, Goregaon (East), Mumbai - 400 063. Tel No: +91 22 4001 3700 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.